GBM's multifaceted landscape: Highlighting regional and microenvironmental heterogeneity

Neuro-Oncology

Volumn 16, Issue 9, 2014, Pages 1167-1175

  Vartanian, Alenoush ^a   Singh, Sanjay K ^a   Agnihotri, Sameer ^a   Jalali, Shahrzad ^a   Burrell, Kelly ^a   Aldape, Kenneth D ^c   Zadeh, Gelareh ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Angiogenesis; Glioblastoma; Hypoxia; Metabolism

Indexed keywords

ANGIOGENESIS; CANCER CELL; CANCER GRADING; CANCER THERAPY; CELL METABOLISM; GENETIC HETEROGENEITY; GENOMIC HETEROGENEITY; GLIOBLASTOMA; HUMAN; HUMAN GENOME; HYPOXIA; IMMUNOCOMPETENT CELL; METABOLIC REPROGRAMMING; MICROENVIRONMENTAL HETEROGENEITY; NEOVASCULARIZATION (PATHOLOGY); NUCLEAR REPROGRAMMING; PERSONALIZED MEDICINE; REGIONAL HETEROGENEITY; REVIEW; STROMA CELL; TUMOR MICROENVIRONMENT; ADULT; BRAIN; BRAIN HYPOXIA; BRAIN TUMOR; CELL PROLIFERATION; COMPLICATION; METABOLISM; PATHOPHYSIOLOGY; VASCULARIZATION;

ADULT; BRAIN; BRAIN NEOPLASMS; CELL PROLIFERATION; GLIOBLASTOMA; HUMANS; HYPOXIA, BRAIN; NEOVASCULARIZATION, PATHOLOGIC; TUMOR MICROENVIRONMENT;

EID: 84905917573     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou035     Document Type: Review

References (108)

1. Central Brain Tumor Registry of the United States. Primary brain and central nervous system tumors diagnosed in the United States in 2004-2006. J Neurooncol. 2013;15:ii1-ii56.
2. Fuller GN, Scheithauer BW. The 2007 revised World Health Organization (WHO) classification of tumours of the central nervous system: newly codified entities. Brain Pathol. 2007;17(3):304-307. (Pubitemid 47000649)
3. Louis DNOH, Wiestler OD, Cavenee WK. WHO Classification of Tumours of the Central Nervous System. Lyon, France: International Agency for Research; 2007.
4. Adamson C, Kanu OO, Mehta AI, et al. Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opin Investig Drugs. 2009;18(8):1061-1083.
5. Bai RY, Staedtke V, Riggins GJ. Molecular targeting of glioblastoma: drug discovery and therapies. Trends Mol Med. 2011;17(6):301-312.
6. Nobusawa S, Lachuer J, Wierinckx A, et al. Intratumoral patterns of genomic imbalance in glioblastomas. Brain Pathol. 2010;20(5):936-944.
7. Kleihues P, Cavenee WK, eds. Pathology and Genetics of Tumours of the Nervous System. World Health Organization Classification of Tumours. Lyon, France: IARC Press; 2000.
8. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359(5):492-507.
9. Rong Y, Durden DL, Van Meir EG, et al. 'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol. 2006;65(6):529-539. (Pubitemid 44288937)
10. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029-1033.
11. Tehrani M, Friedman TM, Olson JJ, et al. Intravascular thrombosis in central nervous system malignancies: a potential role in astrocytoma progression to glioblastoma. Brain Pathol. 2008;18(2):164-171. (Pubitemid 351430394)
12. Brat DJ, Castellano-Sanchez AA, Hunter SB, et al. Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res. 2004;64(3):920-927. (Pubitemid 38176893)
13. Jain RK. Molecular regulation of vessel maturation. Nat Med. 2003;9(6):685-693. (Pubitemid 36749217)
14. Brat DJ, Evans SM. Molecular heterogeneity and tumor microenvironment. In: Mehta MPed. Principles and Practice of Neuro-Oncology: A Multidisciplinary Approach. New York: Demos Medical Publishing; 2010:100-111.
15. Evans SM, Judy KD, Dunphy I, et al. Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding. Cancer Res. 2004;64(5):1886-1892. (Pubitemid 38428715)
16. Yang L, Lin C, Wang L, et al. Hypoxia and hypoxia-inducible factors in glioblastoma multiforme progression and therapeutic implications. Exp Cell Res. 2012;318(19):2417-2426.
17. Evans SM, Judy KD, Dunphy I, et al. Hypoxia is important in the biology and aggression of human glial brain tumors. Clin Cancer Res. 2004;10(24):8177-8184. (Pubitemid 40053376)
18. Bristow RG, Hill RP. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer. 2008;8(3):180-192. (Pubitemid 351301853)
19. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer. 2004;4(6):437-447. (Pubitemid 38745529)
20. Hall EJ, Giaccia AJ. Oxygen Effect and Reoxygenation. In: Hall EJ, Giaccia AJ, eds. Radiobiology for the radiologist. 6th ed. Lippincott Williams & Wilkins; 2006;85-105.
21. Brown JM. Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol Med Today. 2000;6(4):157-162. (Pubitemid 30171366)
22. Yasui H, Asanuma T, Kino J, et al. The prospective application of a hypoxic radiosensitizer, doranidazole to rat intracranial glioblastoma with blood brain barrier disruption. BMC Cancer. 2013;13:106.
23. Nagasawa H, Uto Y, Kirk KL, et al. Design of hypoxia-targeting drugs as new cancer chemotherapeutics. Biol Pharm Bull. 2006;29(12):2335-2342. (Pubitemid 44885846)
24. Engel RH, Kaklamani VG. Role of efaproxiral in metastatic brain tumors. Expert Rev Anticancer Ther. 2006;6(4):477-485. (Pubitemid 44192898)
25. Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 2004;64(19):6892-6899. (Pubitemid 39330996)
26. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061-1068.
27. Sottoriva A, Spiteri I, Piccirillo SG, et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A. 2013;110(10):4009-4014.
28. Bonavia R, Inda MM, Cavenee WK, et al. Heterogeneity maintenance in glioblastoma: a social network. Cancer Res. 2011;71(12):4055-4060.
29. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9(3):157-173. (Pubitemid 43357943)
30. Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010;17(5):510-522.
31. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98-110.
32. Zheng S, Chheda MG, Verhaak RG. Studying a complex tumor: potential and pitfalls. Cancer J. 2012;18(1):107-114.
33. Warburg O. On the origin of cancer cells. Science. 1956;123:309-314.
34. Warburg O. On respiratory impairment in cancer cells. Science. 1956;124(3215):269-270.
35. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
36. Brat DJ, Mapstone TB. Malignant glioma physiology: cellular response to hypoxia and its role in tumor progression. Ann Intern Med. 2003;138(8):659-668. (Pubitemid 38124658)
37. Semenza GL. HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev. 2010;20(1):51-56.
38. Said HM, Hagemann C, Staab A, et al. Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo. Radiother Oncol. 2007;83(3):398-405. (Pubitemid 46907985)
39. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2(1):38-47. (Pubitemid 37328806)
40. Wang GL, Jiang BH, Rue EA, et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A. 1995;92(12):5510-5514.
41. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3(10):721-732. (Pubitemid 37328811)
42. Bulnes S, Bengoetxea H, Ortuzar N, et al. Angiogenic signalling pathways altered in gliomas: selection mechanisms for more aggressive neoplastic subpopulations with invasive phenotype. J Signal Transduct. 2012;2012:Article ID 597915.
43. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell. 2012;21(3):297-308.
44. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, et al. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008;7(1):11-20.
45. Fang M, Shen Z, Huang S, et al. The ER UDPase ENTPD5 promotes protein N-glycosylation, the Warburg effect, and proliferation in the PTEN pathway. Cell. 2010;143(5):711-724.
46. Bauer DE, Hatzivassiliou G, Zhao F, et al. ATP citrate lyase is an important component of cell growth and transformation. Oncogene. 2005;24(41):6314-6322. (Pubitemid 43080054)
47. Berwick DC, Hers I, Heesom KJ, et al. The identification of ATP-citrate lyase as a protein kinase B (Akt) substrate in primary adipocytes. J Biol Chem. 2002;277(37):33895-33900.
48. Green DR, Chipuk JE. p53 and metabolism: inside the TIGAR. Cell. 2006;126(1):30-32.
49. Bensaad K, Tsuruta A, Selak MA, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell. 2006;126(1):107-120. (Pubitemid 44040989)
50. Cantor JR, Sabatini DM. Cancer cell metabolism: one hallmark, many faces. Cancer Discov. 2012;2(10):881-898.
51. Walenta S, Schroeder T, Mueller-Klieser W. Lactate in solid malignant tumors: potential basis of a metabolic classification in clinical oncology. Curr Med Chem. 2004;11(16):2195-2204. (Pubitemid 38967739)
52. Walenta S, Mueller-Klieser WF. Lactate: mirror and motor of tumor malignancy. Semin Radiat Oncol. 2004;14(3):267-274. (Pubitemid 38903231)
53. Michelakis ED, Sutendra G, Dromparis P, et al. Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med. 2010;2(31):31-34.
54. Marie SK, Shinjo SM. Metabolism and brain cancer. Clinics (Sao Paulo). 2011;66(Suppl 1):33-43.
55. Colen CB, Shen Y, Ghoddoussi F, et al. Metabolic targeting of lactate efflux by malignant glioma inhibits invasiveness and induces necrosis: an in vivo study. Neoplasia. 2011;13(7):620-632.
56. Wolf A, Agnihotri S, Micallef J, et al. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med. 2010;208:313-326.
57. Michelakis ED, Webster L, Mackey JR. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer. 2008;99(7):989-994.
58. Lichtor T, Dohrmann GJ. Respiratory patterns in human brain tumors. Neurosurgery. 1986;19(6):896-899. (Pubitemid 17214313)
59. Griguer CE, Oliva CR, Gillespie GY. Glucose metabolism heterogeneity in human and mouse malignant glioma cell lines. J Neurooncol. 2005;74(2):123-133. (Pubitemid 41478907)
60. Hardee ME, Dewhirst MW, Agarwal N, et al. Novel imaging provides new insights into mechanisms of oxygen transport in tumors. Curr Mol Med. 2009;9(4):435-441.
61. Allalunis-Turner MJ, Franko AJ, Parliament MB. Modulation of oxygen consumption rate and vascular endothelial growth factor mRNA expression in human malignant glioma cells by hypoxia. Br J Cancer. 1999;80(1-2):104-109. (Pubitemid 29210095)
62. Parliament MB, Franko AJ, Allalunis-Turner MJ, et al. Anomalous patterns of nitroimidazole binding adjacent to necrosis in human glioma xenografts: possible role of decreased oxygen consumption. Br J Cancer. 1997;75(3):311-318. (Pubitemid 27051043)
63. Turcotte ML, Parliament M, Franko A, et al. Variation in mitochondrial function in hypoxia-sensitive and hypoxia-tolerant human glioma cells. Br J Cancer. 2002;86(4):619-624. (Pubitemid 34185101)
64. Bonuccelli G, Whitaker-Menezes D, Castello-Cros R, et al. The reverse Warburg effect: glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts. Cell Cycle. 2010;9(10):1960-1971.
65. Martinez-Outschoorn UE, Pavlides S, Howell A, et al. Stromal-epithelial metabolic coupling in cancer: integrating autophagy and metabolism in the tumor microenvironment. Int J Biochem Cell Biol. 2011;43(7):1045-1051.
66. Pavlides S, Whitaker-Menezes D, Castello-Cros R, et al. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle. 2009;8(23):3984-4001.
67. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012;21(3):309-322.
68. Marin-Valencia I, Yang C, Mashimo T, et al. Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. Cell Metab. 2012;15(6):827-837.
69. Dhermain FG, Hau P, Lanfermann H, et al. Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol. 2010;9(9):906-920.
70. Yang C, Sudderth J, Dang T, et al. Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res. 2009;69(20):7986-7993.
71. Ko YH, Smith BL, Wang Y, et al. Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun. 2004;324(1):269-275. (Pubitemid 39311489)
72. Ganapathy-Kanniappan S, Vali M, Kunjithapatham R, et al. 3-bromopyruvate: a new targeted antiglycolytic agent and a promise for cancer therapy. Curr Pharm Biotechnol. 2010;11(5):510-517.
73. Rosbe KW, Brann TW, Holden SA, et al. Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro. Cancer Chemother Pharmacol. 1989;25(1):32-36. (Pubitemid 20000795)
74. Carapella CM, Paggi MG, Cattani F, et al. The potential role of lonidamine (LND) in the treatment of malignant glioma. Phase II study. J Neurooncol. 1989;7(1):103-108. (Pubitemid 19160811)
75. Oudard S, Carpentier A, Banu E, et al. Phase II study of lonidamine and diazepam in the treatment of recurrent glioblastoma multiforme. J Neurooncol. 2003;63(1):81-86. (Pubitemid 36681647)
76. Prasanna VK, Venkataramana NK, Dwarakanath BS, et al. Differential responses of tumors and normal brain to the combined treatment of 2-DG and radiation in glioblastoma. J Cancer Res Ther. 2009;5(Suppl 1):S44-S47.
77. Simons AL, Ahmad IM, Mattson DM, et al. 2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer Res. 2007;67(7):3364-3370. (Pubitemid 46724876)
78. Muller FL, Colla S, Aquilanti E, et al. Passenger deletions generate therapeutic vulnerabilities in cancer. Nature. 2012;488(7411):337-342.
79. Zadeh G, Guha A. Angiogenesis in nervous system disorders. Neurosurgery. 2003;53(6):1362-1374; discussion 1374-1376.
80. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3(6):401-410. (Pubitemid 37328844)
81. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86(3):353-364. (Pubitemid 26272076)
82. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97-109. (Pubitemid 47103521)
83. Bulnes S, Bilbao J, Lafuente JV. Microvascular adaptive changes in experimental endogenous brain gliomas. Histol Histopathol. 2009; 24(6):693-706.
84. Korkolopoulou P, Patsouris E, Kavantzas N, et al. Prognostic implications of microvessel morphometry in diffuse astrocytic neoplasms. Neuropathol Appl Neurobiol. 2002;28(1):57-66. (Pubitemid 34175513)
85. Leenders WP, Kusters B, de Waal RM. Vessel co-option: how tumors obtain blood supply in the absence of sprouting angiogenesis. Endothelium. 2002;9(2):83-87. (Pubitemid 35252016)
86. Harrigan MR. Angiogenic factors in the central nervous system. Neurosurgery. 2003;53(3):639-660; discussion 660-661.
87. Hillen F, Griffioen AW. Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev. 2007;26(3-4):489-502. (Pubitemid 350115123)
88. Kioi M, Vogel H, Schultz G, et al. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest. 2010;120(3):694-705.
89. Burrell K, Hill RP, Zadeh G. High-resolution in-vivo analysis of normal brain response to cranial irradiation. PLoS One. 2012;7(6):e38366.
90. Zadeh G, Koushan K, Baoping Q, et al. Role of angiopoietin-2 in regulating growth and vascularity of astrocytomas. J Oncol. 2010;2010:Article ID 659231.
91. Coomber BL, Stewart PA, Hayakawa K, et al. Quantitative morphology of human glioblastoma multiforme microvessels: structural basis of blood-brain barrier defect. J Neurooncol. 1987;5(4):299-307. (Pubitemid 18030539)
92. Nathanson D, Mischel PS. Charting the course across the blood-brain barrier. J Clin Invest. 2011;121(1):31-33.
93. Godard S, Getz G, Delorenzi M, et al. Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res. 2003;63(20):6613-6625. (Pubitemid 37322939)
94. Hendriksen EM, Span PN, Schuuring J, et al. Angiogenesis, hypoxia and VEGF expression during tumour growth in a human xenograft tumour model. Microvasc Res. 2009;77(2):96-103.
95. Di Ieva A. Angioarchitectural morphometrics of brain tumors: are there any potential histopathological biomarkers? Microvasc Res. 2010;80(3):522-533.
96. Di Ieva A, Grizzi F, Sherif C, et al. Angioarchitectural heterogeneity in human glioblastoma multiforme: a fractal-based histopathological assessment. Microvasc Res. 2011;81(2):222-230.
97. Sharma S, Sharma MC, Gupta DK, et al. Angiogenic patterns and their quantitation in high grade astrocytic tumors. J Neurooncol. 2006;79(1):19-30. (Pubitemid 44057411)
98. Birner P, Piribauer M, Fischer I, et al. Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: evidence for distinct angiogenic subtypes. Brain Pathol. 2003;13(2):133-143. (Pubitemid 36460814)
99. Chamberlain MC. Bevacizumab plus irinotecan in recurrent glioblastoma. J Clin Oncol. 2008;26(6):1012-1013; author reply 1013.
100. Zuniga RM, Torcuator R, Jain R, et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol. 2009;91(3):329-336.
101. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008;70(10):779-787.
102. Raizer JJ, Grimm S, Chamberlain MC, et al. A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer. 2010;116(22):5297-5305.
103. Gil-Gil MJ, Mesia C, Rey M, et al. Bevacizumab for the treatment of glioblastoma. Clin Med Insights Oncol. 2013;7:123-135.
104. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15(3):220-231.
105. de Groot JF, Fuller G, Kumar AJ, et al. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol. 2010;12(3):233-242.
106. Chinot OL, de La Motte Rouge T, Moore N, et al. AVAglio: phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv Ther. 2011;28(4):334-340.
107. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996. (Pubitemid 40349501)
108. Yap TA, Workman P. Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics. Annu Rev Pharmacol Toxicol. 2012;52:549-573.